Table 1.
Baseline characteristics for patients who started preoperative chemotherapy and for patients who started postoperative chemotherapy, respectively. Abbreviations: The Netherlands (NL), Denmark (DK), Sweden (SE).
| Variable | Preoperative Chemotherapy | Postoperative Chemotherapy | ||||
|---|---|---|---|---|---|---|
| ECX (n = 632) |
EOX (n = 149) |
p-Value | ECX (n = 182) |
EOX (n = 51) |
p-Value | |
| Age | ||||||
| Median (IQR) | 62 (54–69) | 62 (56–68) | 0.634 | 60 (50–67) | 62 (55–69) | 0.119 |
| Sex | ||||||
| Male | 423 (67%) | 100 (67%) | 0.966 | 130 (71%) | 38 (74.5%) | 0.665 |
| Female | 209 (33%) | 49 (33%) | 52 (29%) | 13 (24.5%) | ||
| WHO PS | ||||||
| missing | 42 | 2 | 0.916 | 12 | 0.584 | |
| 0 | 424 (72%) | 105 (71%) | 128 (75%) | 36 (71%) | ||
| 1 | 166 (28%) | 42 (29%) | 42 (25%) | 15 (29%) | ||
| Tumor localization | ||||||
| GEJ | 107 (17%) | 32 (22%) | 0.179 | 25 (14%) | 9 (18%) | 0.180 |
| Proximal | 120 (19%) | 36 (24%) | 32 (18%) | 15 (29%) | ||
| Middle | 189 (30%) | 39 (26%) | 62 (34%) | 12 (24%) | ||
| Distal | 216 (34%) | 42 (28%) | 63 (35%) | 15 (29%) | ||
| Lauren classification | ||||||
| missing | 147 | 27 | 0.001 | 39 | 14 | 0.042 |
| Diffuse | 211 (44%) | 59 (48%) | 63 (44%) | 17 (46%) | ||
| Intestinal | 223 (46%) | 38 (31%) | 65 (46%) | 11 (29%) | ||
| Mixed | 16 (3%) | 12 (10%) | 3 (2%) | 4 (11%) | ||
| Other | 35 (7%) | 13 (11%) | 12 (8%) | 5 (14%) | ||
| Country of inclusion | ||||||
| NL | 614 (97%) | 2 (1%) | <0.001 | 176 (97%) | 6 (12%) | <0.001 |
| DK | 17 (3%) | 11 (7%) | 5 (3%) | 1 (2%) | ||
| SE | 1 (0%) | 136 (91%) | 1 (0%) | 44 (86%) | ||
| Allocated treatment | ||||||
| Postop CT | 314 (50%) | 78 (52%) | 0.558 | |||
| Postop CRT | 318 (50%) | 71 (48%) | ||||